Our transplant center was asked to evaluate a 44-year-old African American man with Philadelphia chromosomepositive ALL in first remission. Allogeneic blood or marrow transplantation was recommended. He had no HLA-matched siblings, therefore a search for matched unrelated donors was initiated through the National Marrow Donor Program. No suitable matches were identified while he remained in remission receiving chemotherapy, and imatinib mesylate. Acute leukemia relapsed 8 months later, and was refractory to chemotherapy although a hematological remission was achieved with dasatinib. By that time, a suitable unrelated donor (donor A), who had sickle cell trait, had been identified. The alternative options were an HLA-DR antigen-mismatched adult donor and two unrelated umbilical cord blood units (5/6 and 6/6 antigen matched, but each with an insufficient cell count to be used as the sole product). The patient was CMV seronegative; his and the donor HLA types are shown in Table 1 .
Conditioning for transplant consisted of fractionated TBI (1320 cGy; 11 fractions) and VP-16 (60 mg/kg). On the second day of treatment, after the patient had already received a myeloablative radiation dose of 720 cGy, the transplant center was notified that the donor would no longer be available. It was therefore decided that the two unrelated cord blood units, UCBa and UCBb, would be used in combination as the stem cell graft. The conditioning therapy was altered to a regimen of 1320 cGy TBI, followed by 25 mg/m 2 fludarabine daily for 3 days with 60 mg/kg cyclophosphamide on each of the last 2 days. Cyclosporin and mycophenolate were started on day 1. Cord blood unit UCBb was infused on day 0, within 6 days of the request by National Marrow Donor Program. As this infusion was complicated by the development of malignant hypertension, FK-506 was substituted for cyclosporine and the infusion of the second cord blood unit was delayed until the next day. G-CSF and the usual supportive care were given.
The patient developed pneumonia and coagulasenegative staphylococcemia while neutropenic; these were successfully treated with antibiotics. His absolute neutrophil count recovered to 1000/ml on day 29; G-CSF was discontinued. The platelet count recovered to 20 000/ml independent of transfusions on day 37. Chimerism studies by small tandem repeat PCR on day 32 (peripheral blood) and day 98 (peripheral blood T and B lymphocytes, bone marrow) showed complete donor chimerism of cord blood unit UCBb. Mycophenolate was stopped on day 85, and FK-506 was weaned off between days 150 and 210. In the last assessment 364 days after transplant, the bone marrow and the peripheral blood studies continued to show full donor chimerism (cord blood unit UCBb) and complete remission of leukemia including absence of bcr abl by PCR. To date, the patient has not developed acute or chronic GVHD. He has returned to work.
Figures made available by the National Marrow Donor Program (see Table 2 ) show that fewer unrelated cord blood than adult blood and marrow searches are requested during the preliminary phase, and an even smaller percentage of the former are carried to a formal search. 1 However, the same proportions of formal searches of cord blood and adult marrow/stem cell donors culminate in transplant. Cord blood transplants are associated with a shorter time from preliminary or formal searching to transplant 2 and do not need a period of donor medical evaluation 'work-up' once selected. This may be more important among minorities and individuals with rare HLA types.
Approximately 20% of adult marrow/stem cell donors are deferred during their medical evaluation ('work-up') phase just prior to transplant. 1 These late deferrals present a serious problem to potential recipients and their treating physicians, particularly when alternative adult marrow/ stem cell donors are unavailable. Deferrals occurring after the receipt of myeloablative therapy (very late deferrals), although fortunately rare, are even more critical and pose an urgent need for stem cells similar to what might be expected after failed engraftment or other forms of iatrogenic, accidental or even warfare-/terrorism-related myeloablative injury. [3] [4] [5] A similar situation could also arise with family donors, especially among minorities or others with rare HLA types. This case illustrates the usefulness of identifying back-up unrelated cord blood units in cases where late or very late deferral of the marrow/stem cell donor would be catastrophic because of time constraints and/or the lack of alternative adult marrow/stem cell donors. Table 2 is derived from the data published by the National Marrow Donor Program. 
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